IPF is characterized as a progressive, highly life-threatening interstitial lung disease with unknown etiology. The median survival of patients with IPF is only 2 to 3 years. It occurs primarily in elders, is limited to the lungs, and is defined by the histopathologic and/or radiologic pattern of UIP. It should be considered in all adult patients with unexplained chronic exertional dyspnea, cough, bibasilar inspiratory crackles, and/or digital clubbing that occur without constitutional or other symptoms that suggest a multisystem disease. Patients with IPF may present with an acute exacerbation as an initial manifestation. The disease course is unpredictable and various, so early IPF detection and immediate treatment are crucial to the preservation of patients’ lung function. In this meeting, we will present the latest IPF clinical information and IPF/ILD differential diagnosis via multiple disciplinary discussions for your reference.